Global Anti-Asthma Drugs Market Size, Share and Trends Analysis Report,By Type (Long-term Control Medications, Quick-relief Medications (Rescue Medications), and Medications for Allergy-induced Asthma), By Application (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Forecast (2022-2028)

The global anti-asthma drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Asthma is a chronic inflammatory lung disorder of the airways that is not communicable. The rise in the prevalence of asthma and COPD is driving the global Asthma and COPD Drugs Market’s expansion. For instance, in 2019 the World Health Organization (WHO) estimates that asthma affected 262 million people and killed 46,1000 people. Furthermore, the increasing number of COPD patients contributes to market expansion. Millions of adults in the United States had chronic bronchitis, and 2 million adults had emphysema, according to the American Lung Organization.

Furthermore, advancements in respiratory disease therapy and new product launches are expected to contribute to the market’s growth in the global Asthma and Chronic Obstructive Pulmonary Disease Drugs Market. For instance, in December 2020, AstraZeneca, a leading pharmaceutical manufacturer, received EU approval for ‘Trixeo Aerosphere’ for COPD maintenance treatment. The high cost of associated asthma treatment, on the other hand, limits market growth during the forecast period.

E-cigarettes are becoming more popular as a tobacco-free alternative. Because it contains nicotine extracts from tobacco, e-cigarette smoking/vaping increases the risk of developing asthma in individuals. E-cigarettes, also known as e-cigs, vaporizer cigarettes, and vape pens, are electronic battery-powered devices that emit doses of vaporised nicotine or non-nicotine solutions to provide the user with the sensation of inhaling tobacco. The popularity of e-cigarettes is growing. In the United States, for instance, as of 2020, 19.6 percent of high school students and 4.7 percent of middle school students had used an e-cigarette. The number of e-cigarette users is expected to rise further. Rising e-cigarette use is expected to increase the number of asthma patients during the forecast period.

There is a large population of undiagnosed people who will contribute to the growth of the anti-asthmatic drugs market. A sizable portion of the global population is unaware of their respiratory diseases and goes undiagnosed. For instance,  in 2019, a large population in China was at risk of COPD according to the global public health journal ‘BMC Public Health.’ It was estimated that approximately 105.3 million adult urban Chinese residents were at risk of having undiagnosed COPD.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- GlaxoSmithKline Plc, Merck & Co Inc., AstraZeneca Plc, BoehringerIngelheim GmbH, Novartis AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Anti-Asthma Drugs Market Report by Segment

By Type

• Long-term Control Medications
• Quick-relief Medications (Rescue Medications)
• Medications for Allergy-induced Asthma

By Indication

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Anti-Asthma Drugs Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa